Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 309Neoplasms 269Prostatic Neoplasms 189Precursor Cell Lymphoblastic Leukemia-Lymphoma 186Lymphoma 184Leukemia, Lymphocytic, Chronic, B-Cell 161Melanoma 158Leukemia 154Lymphoma, Non-Hodgkin 149Leukemia, Myeloid, Acute 149Brain Neoplasms 143Carcinoma, Non-Small-Cell Lung 141Lymphoma, Large B-Cell, Diffuse 128Colonic Neoplasms 128Lymphoma, Follicular 123Burkitt Lymphoma 119Ovarian Neoplasms 117Lung Neoplasms 116Glioblastoma 116Lymphoma, Mantle-Cell 114Unspecified Adult Solid Tumor, Protocol Specific 107Rectal Neoplasms 103Sarcoma 102Multiple Myeloma 102Gliosarcoma 102Hodgkin Disease 97Carcinoma, Renal Cell 97Lymphoma, B-Cell, Marginal Zone 96Astrocytoma 95Carcinoma, Ovarian Epithelial 93

Interventions

Spironolactone 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × NIH × Acanthosis Nigricans × Clear all
NCT00004311 2005-06-24

Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome

Office of Rare Diseases (ORD)

Phase 2 Completed

Acanthosis Nigricans, Endocrine System Diseases, Polycystic Ovary Syndrome, Skin Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡